Abiopharma

🔍 Latchana David A (Executive)

Company: WOLVERINE WORLD WIDE INC /DE/ (WWW)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Acquired 2,609 shares of Common Stock (Direct)
  Date: 2026-04-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 30,680.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 949 shares of Common Stock at $16.91 per share (Direct)
  Date: 2026-04-29 | Code: F | equity_swap_involved: 0 | shares_owned_after: 29,731.00 | transaction_form_type: 4
• Sold 2,609 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,610.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Restricted stock units convert into shares of Common Stock on a one-for-one basis.
• F2: On April 29, 2024, the Reporting Person was granted 7,829 restricted stock units, vesting as follows, subject to the Reporting Person's continued employment: one-third on each of the first, second, and third year anniversaries of the grant date.